After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Antibodies are the cardinal effector molecules of the immune system and are being
leveraged with enormous success as biotherapeutic drugs. A key part of the adaptive …

Antibody responses develop following SARS-CoV-2 infection, but little is known about their
epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We …

INTRODUCTION Immunoglobulin A (IgA) is the most abundant mammalian antibody
isotype, constituting more than 80% of all antibody-secreting plasma cells at steady state …

Antibodies are a highly successful class of biological drugs, with over 50 such molecules
approved for therapeutic use and hundreds more currently in clinical development …

Various immune mechanisms are deployed in the mucosa to confront the immense diversity
of resident bacteria. A substantial fraction of the commensal microbiota is coated with …

HIV employs multiple means to evade the humoral immune response, particularly the
elicitation of and recognition by broadly neutralizing antibodies (bnAbs). Such antibodies …

SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier
and caused widespread disease in the past two decades. The development of a universal …

Traditionally, vaccines have been developed by cultivating infectious agents and isolating
the inactivated whole pathogen or some of its purified components. 20 years ago, reverse …

Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing
antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of …